Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 9
Total Novo Nordisk basal insulin volume market share has
increased to 34% in the US
Weekly TRX volume market shares in the US
-
glargine U100
Basal volume
TRX MS
70%
60%
50%
40%
30%
20%
10%
0% +
NN Total Basal
TresibaⓇ
Levemir®
glargine U300
biosimilar glargine U100
TresibaⓇ launch in the US
• The ambition to reach 10% TresibaⓇ TRX volume market
share in 2017 achieved
• TresibaⓇ TRX volume market share is now 10.7%
• TresibaⓇ formulary access expected to remain largely
unchanged at approximately 70% for commercial and
Medicare Part D combined in 2018
45%
.34%
23%
11%
8%
6%
access
Opportunity for TresibaⓇ to grow volume market share
further in early 2018 due to changes in the Part D formulary
Jan
2016
Jan
2018
Note: The graph does not show NPH, which accounts for the residual market share
Source: IQVIA weekly Xponent Plantrak (excludes Medicaid), 12 Jan 2018
TRX volume: Insulin volume in mega units (MU) associated with total number of prescriptions;
MS: Market share
Source: IQVIA weekly Xponent Plantrak (excludes Medicaid), 12 Jan, 2018, VANTAGE
FingerTip Formulary bridge, Nov 2017
novo nordiskView entire presentation